PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis
- 10 February 2016
- journal article
- review article
- Published by Elsevier BV in Critical Reviews in Oncology/Hematology
- Vol. 100, 88-98
- https://doi.org/10.1016/j.critrevonc.2016.02.001
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Programmed Death Ligand 2 in Cancer-Induced Immune SuppressionClinical and Developmental Immunology, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityThe Journal of Experimental Medicine, 2010
- Analysis of the reporting of search strategies in Cochrane systematic reviewsJournal of the Medical Library Association, 2009
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Advanced methods in meta‐analysis: multivariate approach and meta‐regressionStatistics in Medicine, 2002
- The QUORUM statementThe Lancet, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000